8-K: Lifeward Ltd. CEO Departs, Interim CEO Appointed
Current Report
Lifeward Ltd. announced the departure of its President and CEO, Mark Grant, effective August 31, 2026, with Josh Hexter appointed as Interim CEO and Rami Aviram as CFO.
Summary
- Mark Grant has departed from his roles as President and CEO of Lifeward Ltd. and as a member of the Board of Directors, effective August 31, 2026.
- Josh Hexter has been appointed as the Interim Chief Executive Officer, effective September 1, 2026.
- Rami Aviram has been appointed as the Chief Financial Officer, effective November 1, 2026.
- Mr. Grant will serve as a Senior Advisor through September 30, 2026, for a consulting fee of $40,000.
- Mr. Grant's departure is not due to any disagreements with the Company.
- Mr. Hexter currently serves as Chief Operating and Business Officer of Oramed Pharmaceuticals Inc., the controlling shareholder.
- Mr. Aviram's previous role was CFO of Beewise Technologies Ltd.
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a neutral to slightly negative development due to the departure of the CEO, although the appointment of an interim CEO and a new CFO provides some stability.
Positives
- Orderly transition facilitated by a consulting agreement with the departing CEO.
- Appointment of an experienced interim CEO with nearly three decades of life sciences industry experience.
- Appointment of an experienced CFO with a background in technology and global finance.
- The departure of the CEO is not attributed to any disagreements with the company.
Negatives
- Departure of the President and CEO, Mark Grant.
- The new interim CEO, Josh Hexter, will substantially reduce his responsibilities at Oramed Pharmaceuticals Inc., indicating a significant shift in focus.
- The appointment of Rami Aviram as CFO is effective November 1, 2026, leaving a period where an interim principal financial officer will be needed.
Risks
- Potential disruption to operations and strategy due to CEO transition.
- Uncertainty regarding the long-term leadership of the company.
- Integration challenges for the new interim CEO and CFO.
- Shareholder approval required for the interim CEO's employment terms.
Future Outlook
The filing does not contain specific forward-looking financial guidance. The focus is on executive leadership changes and transition plans.
Management Comments
- Mr. Grant's departure is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- Mr. Hexter brings nearly three decades of leadership, business development, operations and management experience in the life sciences industry.
- Mr. Aviram is an experienced global finance executive.
Industry Context
StockSavvy.ai notes that executive turnover, particularly at the CEO level, is a common event in the life sciences industry, often driven by strategic shifts, funding challenges, or performance pressures. The appointment of an interim CEO from a controlling shareholder (Oramed Pharmaceuticals) suggests a desire for continuity and potentially closer alignment with the parent entity during the transition.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President and Chief Executive Officer | Mark Grant | Josh Hexter (Interim) | September 1, 2026 | Departure of Mark Grant |
| Member of the Board of Directors | Mark Grant | N/A | August 31, 2026 | Departure of Mark Grant |
| Chief Financial Officer | Almog Adar | Rami Aviram | November 1, 2026 | Departure of Almog Adar |
| Principal Executive Officer | Mark Grant | Josh Hexter | September 1, 2026 | Departure of Mark Grant |
| Principal Financial Officer | Almog Adar | Rami Aviram | November 1, 2026 | Departure of Almog Adar |
| Principal Accounting Officer | Almog Adar | Rami Aviram | November 1, 2026 | Departure of Almog Adar |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Employment Agreement Approval | The Compensation Committee and Board approved the employment agreement for Interim CEO Josh Hexter, which will be submitted for shareholder approval. | September 1, 2026 | Ensures compliance with regulations for transactions with interested parties and seeks shareholder buy-in for executive compensation. |
| Employment Agreement Approval | The Compensation Committee and Board approved the employment agreement for CFO Rami Aviram. | November 1, 2026 | Formalizes the terms of employment for the new CFO. |
Related Party Transactions
- Josh Hexter's appointment as Interim CEO is in connection with his continuing service as Chief Operating and Business Officer of Oramed Pharmaceuticals Inc., the controlling shareholder, in a substantially reduced capacity.
- The company entered into a separation agreement and consulting agreement with former CEO Mark Grant.
Stakeholder Impact
- Shareholders: Potential uncertainty due to CEO transition, but stability provided by interim appointments and experienced new CFO. Shareholder approval needed for interim CEO's compensation.
- Employees: Potential impact on morale and operational continuity due to CEO departure; clarity on interim leadership may mitigate concerns.
- Creditors/Suppliers: No immediate direct impact indicated, but long-term strategic direction under new leadership could influence future business relationships.
Next Steps
- Shareholder approval for Josh Hexter's employment agreement at the next general meeting.
- Lifeward Ltd. to file its Quarterly Report on Form 10-Q for the quarter ending September 30, 2026, which will include copies of the Separation and Consulting Agreements and the Hexter Employment Agreement as exhibits.
Key Dates
| Date | Description |
|---|---|
| August 31, 2026 | Effective date of Mark Grant's departure as President and CEO and Board member; Date of Separation Agreement and Consulting Agreement execution. |
| September 1, 2026 | Effective date of Josh Hexter's appointment as Interim CEO; Start of Mr. Grant's consulting services. |
| September 30, 2026 | End date of Mark Grant's consulting services as Senior Advisor. |
| October 2026 | End date of Rami Aviram's tenure as CFO at Beewise Technologies Ltd. |
| October 31, 2026 | Effective date of Rami Aviram's appointment as CFO. |
| November 1, 2026 | Effective date of Rami Aviram's appointment as CFO. |
| September 30, 2026 | Quarter end for which Lifeward Ltd. will file its Form 10-Q, including Separation and Consulting Agreements as exhibits. |
Recommendation
holdThe departure of a CEO is a significant event that introduces uncertainty. While the appointment of an interim CEO and a new CFO with relevant experience provides some stability, the lack of a permanent CEO and the ongoing transition period warrant a cautious 'hold' stance until a permanent leadership is established and a clear strategic direction is communicated.
Keywords
CEO Departure, Interim CEO Appointment, CFO Appointment, Executive Transition, Board of Directors, Lifeward Ltd., Oramed Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.